GKOS
GLAUKOS Corp
Next earnings Jul 28, 2026 · consensus $-0.22 EPS, $154M rev
Last earnings -2.2% on 2026-04-29
$142.57
▲ +3.49%$142.57▲ +42.36%
over 1Y
L $74.67EODHDH $144.01
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.5%
1W+9.1%
1M+24.0%
3M+32.3%
YTD+28.8%
1Y+42.4%
Hold
Conviction
Horizon
Long (>12mo)
Street · 21 analysts
Buy
Fast-growing ophthalmic device maker with 56% gross margins and accelerating sales, but still deeply loss-making at a steep 15x revenue.
Glaukos is a high-growth ophthalmic medical-device company (glaucoma micro-stents and the iDose sustained-release platform) showing strong commercial momentum: FY2025 revenue grew 32.3% to $507M, accelerating from prior years (revenue has climbed from $294M in FY2021), with healthy 55.7% gross margins that confirm attractive underlying device economics. Operating cash flow improved sharply to nearly breakeven (-$14.8M, +75.9%), suggesting the model is approaching self-funding even as it scales.
Sources: SEC EDGAR (CIK 0001192448, latest 10-Q filed 2026-04-30) · EODHD · analysis by claude-code · as of 6/21/2026, 8:52:34 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.